ClinicalTrials.gg
RecruitingNCT07547423Updated Oct 7, 2026

Auricular Laser Acupuncture for Improving Sleep in Breast Cancer Patients

An interventional study of auricular laser acupuncture and sham auricular laser acupuncture in Breast Cancer Females and Insomnia, sponsored by CHING-RONG HUANG. Recruiting at 1 site in Taiwan. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by CHING-RONG HUANG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 125 studies in Sleep Initiation and Maintenance Disorders with a site in Taiwan — 36 open to participants now, 38 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Taiwan.

Planned enrollment
66th of 118
70 · median 76
Started
2026
with 16 others
No phase
113 of 125
35 open now
Primary completion
2027-06
later than 22 of 37 live
Registered
99th of 125
by date

Among the 125 studies in Sleep Initiation and Maintenance Disorders with a site in Taiwan, this one is the 66th largest by planned enrollment of the 118 interventional ones that give a count, is one of 17 that started in 2026, is one of 113 with no phase, reaches primary completion later than 22 of the 37 other live ones, and was the 99th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

36 of the 125 studies in Sleep Initiation and Maintenance Disorders with a site in Taiwan are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Sleep Initiation and Maintenance Disorders with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if auricular laser acupuncture can improve sleep quality and alleviate related symptoms in female breast cancer patients aged 18 to 75 with insomnia. The main questions it aims to answer are:

  1. Does active auricular laser acupuncture improve sleep quality and reduce the severity of insomnia?
  2. Does it help lower levels of cancer-related fatigue, anxiety, and depression?

Researchers will compare an active auricular laser acupuncture group to a sham control group (receiving no therapeutic laser energy) to see if active laser acupuncture is effective for symptom relief.

Participants will:

  1. Receive 10 sessions of laser treatment (active or sham) twice a week for 5 weeks, while wearing protective goggles to ensure blinding.
  2. Wear an actigraphy wristband and keep a sleep diary to monitor sleep patterns, and undergo heart rate variability (HRV) measurements at baseline and Week 5 (post-treatment).
  3. Complete questionnaires assessing sleep, fatigue, mood, and quality of life at baseline, Week 5 (post-treatment), and Week 10 (follow-up).
03

Conditions studied

  • Breast Cancer Females
  • Insomnia

Keywords

  • Breast Cancer
  • Insomnia
  • Auricular Laser Acupuncture
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years.
  • confirmed breast cancer, TNM stage I-III.
  • Meets the diagnostic criteria for insomnia.
  • Willing to participate in the study (completion of at least 8 out of 10 treatment sessions).
  • Able to provide signed .
  • No use of sedative-hypnotic medications other than Stilnox, Ativan, Xanax, or Eurodin within the past three months.

Exclusion criteria

Exclusion Criteria:

  • Currently undergoing or planning to undergo chemotherapy, radiotherapy, or surgical treatment during the study period.
  • Other sleep disorders (e.g., sleep apnea, restless legs syndrome).
  • Severe physical or psychiatric comorbidities.
  • Has an implanted cardiac pacemaker.
  • History of epilepsy.
  • Taking gametocides or .
  • Pregnant.
  • Substance abuse or alcoholism.
  • Participated in other clinical trials within the past three months, or concurrent participation during the study period.
  • Unable to cooperate with the assessment procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    laser acupuncture

    Device: auricular laser acupuncture

  • Sham comparator
    sham laser acupuncture

    Device: sham auricular laser acupuncture

Interventions

  • Deviceauricular laser acupuncture

    Using laser pen to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)

  • Devicesham auricular laser acupuncture

    Using laser pen WITH NO LASER OUTPUT to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)

06

What researchers measure

Primary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Total scores range from 0 to 21. Higher scores indicate a worse outcome (poorer sleep quality).

    Time frame: base line, 5 weeks (after treatment session)

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Total scores range from 0 to 21. Higher scores indicate a worse outcome (poorer sleep quality).

    Time frame: baseline, 10 weeks (follow up)

  2. Objective Sleep Efficiency Assessed by Actigraph

    Objective parameters are recorded via wrist-worn ActiGraph monitor over 7 continuous days (5 weekdays, 2 weekends) per assessment to calculate daily averages. Metrics include: 1. Sleep Efficiency: Ratio of Total Sleep Time to Time in Bed (range: 0-100%). Higher values indicate a better outcome. 2. Total Sleep Time: Measured in minutes. Higher values indicate a better outcome. 3. Sleep Latency: Measured in minutes. Lower values indicate a better outcome. 4. Wake After Sleep Onset (WASO): Measured in minutes. Lower values indicate a better outcome. 5. Number of Awakenings: Count per period. Lower values indicate a better outcome. 6. Average Awakening Duration: Measured in minutes. Lower values indicate a better outcome.

    Time frame: baseline, 5 weeks (after treatment session)

  3. Subjective Sleep Quality Assessed by Sleep Diary

    Subjective sleep parameters are recorded via daily sleep diary over 7 continuous days (5 weekdays, 2 weekends) per assessment to calculate daily averages. Metrics include: 1. Subjective Sleep Quality: Self-rated 5-point scale (range: 1-5; 1=Very Poor, 5=Very Good). Higher scores indicate a better outcome. 2. Total Sleep Time: Measured in minutes. Higher values indicate a better outcome. 3. Sleep Latency: Measured in minutes. Lower values indicate a better outcome. 4. Number of Awakenings: Count per night. Lower values indicate a better outcome. 5. Night Awakening Duration: Measured in minutes. Lower values indicate a better outcome.

    Time frame: baseline, 5 weeks (after treatment session)

  4. Autonomic Nervous System Function Assessed by Short-Term Heart Rate Variability (HRV)

    Short-term (5-minute) resting HRV is measured to evaluate autonomic nervous system function. The metrics extracted for analysis include: 1. SDNN (Standard Deviation of NN intervals): Measured in milliseconds (ms). Higher values indicate a better outcome. 2. Total Power (TP): Measured in ms². Higher values indicate a better outcome. 3. HF (High Frequency power): Reflects parasympathetic activity, measured in ms². Higher values indicate a better outcome. 4. LF/HF Ratio: Calculated as the ratio of Low Frequency to High Frequency power. Lower values indicate a better outcome (reduced sympathetic hyperarousal).

    Time frame: baseline, 5 weeks (after treatment session)

  5. Functional Assessment of Cancer Therapy - Breast (FACT-B)

    Total scores range from 0 to 148. Higher scores indicate a better outcome (better health-related quality of life).

    Time frame: baseline, 5 weeks (after treatment session), 10 weeks (follow up)

  6. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue)

    Total scores range from 0 to 52. Higher scores indicate a better outcome (less fatigue).

    Time frame: baseline, 5 weeks (after treatment session), 10 weeks (follow up)

  7. Generalized Anxiety Disorder-7 (GAD-7)

    Total scores range from 0 to 21. Higher scores indicate a worse outcome (greater severity of anxiety).

    Time frame: baseline, 5 weeks (after treatment session), 10 weeks (follow up)

  8. Patient Health Questionnaire-9 (PHQ-9)

    Total scores range from 0 to 27. Higher scores indicate a worse outcome (greater severity of depression).

    Time frame: baseline, 5 weeks (after treatment session), 10 weeks (follow up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Aug 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 23, 2026
StartActual
Aug 26, 2026was Apr 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Chung Shan Medical University Hospital is now Recruiting
Oct 7, 2026
Start date
Apr 1, 2026→Aug 26, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Chung Shan Medical University Hospital is now Recruiting
    Start date Apr 1, 2026→Aug 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07547423
Lead sponsor
CHING-RONG HUANG
Responsible party
CHING-RONG HUANG (Attending Physican, Chung Shan Medical University) — Sponsor-investigator
First posted
Apr 23, 2026
Start date
Aug 26, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Ching-Rong Huang
Contact
csh.y2080@gmail.com
+886-4-24739595 #38206

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion